{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:51:53Z","timestamp":1785268313589,"version":"3.55.0"},"reference-count":157,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":2784,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s13311-015-0398-y","type":"journal-article","created":{"date-parts":[[2015,10,28]],"date-time":"2015-10-28T11:27:56Z","timestamp":1446031676000},"page":"118-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis"],"prefix":"10.1016","volume":"13","author":[{"given":"Jeffrey T.","family":"Guptill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew N.","family":"Meriggioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0398-y_bib1","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/B978-0-444-59565-2.00015-0","article-title":"Autoimmune myasthenia gravis","volume":"113","author":"Jayawant","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.expneurol.2015.02.010","article-title":"Thymoma related myasthenia gravis in humans and potential animal models","volume":"270","author":"Marx","year":"2015","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib4","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"1","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1007\/s13311-015-0398-y_bib5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/WCO.0000000000000136","article-title":"Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis","volume":"27","author":"Reddel","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib6","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: Predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-015-0398-y_bib8","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0398-y_bib9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0398-y_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1007\/s13311-015-0398-y_bib11","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1073\/pnas.87.19.7792","article-title":"Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis","volume":"87","author":"Protti","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0398-y_bib12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1212\/WNL.50.4.1045","article-title":"T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis","volume":"50","author":"Wang","year":"1998","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0398-y_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s13311-015-0398-y_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/08916930903555935","article-title":"Thymoma and paraneoplastic myasthenia gravis","volume":"43","author":"Marx","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1007\/s13311-015-0398-y_bib15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.autrev.2013.03.010","article-title":"Etiology of myasthenia gravis: Innate immunity signature in pathological thymus","volume":"12","author":"Cavalcante","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1007\/s13311-015-0398-y_bib16","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4049\/jimmunol.167.4.1935","article-title":"Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis","volume":"167","author":"Sims","year":"2001","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib17","first-page":"213092","article-title":"Inflammation and Epstein-Barr virus infection are common features of myasthenia gravis thymus: possible roles in pathogenesis","volume":"2011","author":"Cavalcante","year":"2011","journal-title":"Autoimmune Dis"},{"key":"10.1007\/s13311-015-0398-y_bib18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(78)90073-9","article-title":"In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis","volume":"1","author":"Vincent","year":"1978","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0398-y_bib19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/blood-2005-06-2383","article-title":"The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis","volume":"108","author":"Meraouna","year":"2006","journal-title":"Blood"},{"issue":"9 Suppl. 2","key":"10.1007\/s13311-015-0398-y_bib20","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1097\/JTO.0000000000000299","article-title":"Alterations of the immune system in thymic malignancies","volume":"9","author":"Weksler","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1007\/s13311-015-0398-y_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0398-y_bib22","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction","volume":"63","author":"Cole","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/BOR.0b013e3283412fd4","article-title":"What is IgG4? A review of the biology of a unique immunoglobulin subtype","volume":"23","author":"Nirula","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1007\/s13311-015-0398-y_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/cei.12641","article-title":"Immunology of IgG4-related disease","volume":"181","author":"Della-Torre","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2013.12.005","article-title":"Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis","volume":"52","author":"Yi","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1007\/s13311-015-0398-y_bib27","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1212\/NXI.0000000000000077","article-title":"Characterization of B Cells in Muscle Specific Kinase Antibody Myasthenia Gravis","volume":"2","author":"Guptill","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1007\/s13311-015-0398-y_bib28","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib29","first-page":"191","article-title":"Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis","volume":"181","author":"Shen","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib30","doi-asserted-by":"crossref","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","article-title":"Autoantibodies to agrin in myasthenia gravis patients","volume":"9","author":"Gasperi","year":"2014","journal-title":"PLoS One"},{"key":"10.1007\/s13311-015-0398-y_bib31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archneur.62.3.442","article-title":"Striational antibodies in myasthenia gravis. Reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib32","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1007\/s13311-015-0398-y_bib33","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0398-y_bib34","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib35","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0398-y_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.20515","article-title":"Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody","volume":"34","author":"Punga","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0398-y_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000116785","article-title":"Long-term results of corticosteroid therapy in patients with myasthenia gravis","volume":"32","author":"Evoli","year":"1992","journal-title":"Eur Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/WNL.34.2.170","article-title":"Myasthenia gravis: prolonged treatment with steroids","volume":"34","author":"Sgirlanzoni","year":"1984","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0398-y_bib41","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1212\/WNL.36.5.729","article-title":"Prednisone-induced worsening of neuromuscular function in myasthenia gravis","volume":"36","author":"Miller","year":"1986","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0398-y_bib42","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0398-y_bib43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1007\/s13311-015-0398-y_bib44","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0277-5379(91)90179-H","article-title":"Extrathymic malignancy in patients with myasthenia gravis","volume":"27","author":"Monden","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1007\/s13311-015-0398-y_bib45","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ibd.20211","article-title":"Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?","volume":"13","author":"Jones","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1007\/s13311-015-0398-y_bib46","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1526-0968.2000.004004275.x","article-title":"Therapeutic apheresis in myasthenia gravis","volume":"4","author":"Batocchi","year":"2000","journal-title":"Ther Apher"},{"key":"10.1007\/s13311-015-0398-y_bib48","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0398-y_bib49","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0398-y_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0404.2006.00609.x","article-title":"Myasthenia gravis: disease severity and prognosis","volume":"183","author":"Romi","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1007\/s13311-015-0398-y_bib51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0398-y_bib52","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0398-y_bib53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0398-y_bib54","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib55","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/08916931003674741","article-title":"Targeting lymphocyte co-stimulation: from bench to bedside","volume":"43","author":"Felix","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1007\/s13311-015-0398-y_bib56","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4110\/in.2013.13.5.184","article-title":"Emerging co-signaling networks in T cell immune regulation","volume":"13","author":"Jung","year":"2013","journal-title":"Immune Netw"},{"key":"10.1007\/s13311-015-0398-y_bib57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib58","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev.iy.07.040189.002305","article-title":"Clonal expansion vs functional clonal inactivation: a costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy","volume":"7","author":"Mueller","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib59","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s40265-013-0080-9","article-title":"Abatacept: a review of its use in the management of rheumatoid arthritis","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"key":"10.1007\/s13311-015-0398-y_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40259-012-0001-6","article-title":"Targeting the B7 family of co-stimulatory molecules: successes and challenges","volume":"27","author":"Podojil","year":"2013","journal-title":"BioDrugs"},{"key":"10.1007\/s13311-015-0398-y_bib61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn's disease and ulcerative colitis","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1007\/s13311-015-0398-y_bib62","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib63","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","article-title":"Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-\u03b1","volume":"52","author":"Gradolatto","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1007\/s13311-015-0398-y_bib64","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0165-5728(02)00228-X","article-title":"Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence","volume":"130","author":"Wang","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0398-y_bib65","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2014.4103","article-title":"A genome-wide association study of myasthenia gravis","volume":"72","author":"Renton","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib66","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0896-8411(03)00119-7","article-title":"Regulation of immune and autoimmune responses by ICOS","volume":"21","author":"Dong","year":"2003","journal-title":"J Autoimmun"},{"key":"10.1007\/s13311-015-0398-y_bib67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2004.04.019","article-title":"ICOS is essential for the development of experimental autoimmune myasthenia gravis","volume":"153","author":"Scott","year":"2004","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0398-y_bib68","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2009.03.023","article-title":"Defining dose-response relationships in the therapeutic blockade of B7RP-1-dependent immune responses","volume":"610","author":"Metz","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-015-0398-y_bib69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-2776(10)05003-0","article-title":"OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology","volume":"105","author":"Ishii","year":"2010","journal-title":"Adv Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib70","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1007\/s13311-015-0398-y_bib71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1189\/jlb.0310154","article-title":"GM-CSF-induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms","volume":"89","author":"Bhattacharya","year":"2011","journal-title":"J Leukoc Biol"},{"key":"10.1007\/s13311-015-0398-y_bib72","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.expneurol.2014.04.015","article-title":"Daclizumab (anti-CD25) in multiple sclerosis","volume":"262","author":"Pfender","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib73","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","article-title":"Naturally arising CD4+ regulatory T cells for immunologoic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib74","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.smim.2003.12.002","article-title":"Molecular aspects of regulatory T cell development","volume":"16","author":"Fontenot","year":"2004","journal-title":"Semin Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib75","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1074-7613(02)00298-4","article-title":"The impact of T helper and T regulatory cells in the regulation of anti-double-stranded DNA B cells","volume":"16","author":"Seo","year":"2002","journal-title":"Immunity"},{"key":"10.1007\/s13311-015-0398-y_bib76","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.4049\/jimmunol.0901163","article-title":"Cutting edge: regulatory T cells directly suppress B cells in systemic lupus erythematosis","volume":"183","author":"Iikuni","year":"2009","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib77","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.4049\/jimmunol.1002942","article-title":"Foxp3+ regulatory T cells control humoral autoimmunity by suppressing the development of long-lived plasma cells","volume":"186","author":"Jang","year":"2011","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib78","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.0300-9475.2004.01410.x","article-title":"Circulating CD4+CD25+ and CD4+CD25+ Tcells in myasthenia gravis and in relation to thymectomy","volume":"59","author":"Huang","year":"2004","journal-title":"Scand J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib79","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.imlet.2008.11.015","article-title":"The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis","volume":"122","author":"Zhang","year":"2009","journal-title":"Immunol Lett"},{"key":"10.1007\/s13311-015-0398-y_bib80","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical implication of peripheral CD4+ CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients","volume":"225","author":"Masuda","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0398-y_bib81","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clim.2012.09.012","article-title":"Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low\/-) T cells in patients with myasthenia gravis","volume":"145","author":"Thiruppathi","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib82","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.humimm.2009.01.016","article-title":"Dendritic cell tolerance: a key mechanism in immunomodulation by vitamin D receptor agonists","volume":"70","author":"Adorini","year":"2009","journal-title":"Hum Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib83","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib84","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4049\/jimmunol.0802046","article-title":"Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients","volume":"83","author":"Luther","year":"2009","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib85","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib86","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jneuroim.2006.04.011","article-title":"Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms","volume":"176","author":"Zhu","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0398-y_bib87","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.imlet.2013.07.005","article-title":"The CD40\/CD40L system: a new therapeutic target for disease","volume":"153","author":"Zhang","year":"2013","journal-title":"Immunol Lett"},{"key":"10.1007\/s13311-015-0398-y_bib88","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.4049\/jimmunol.166.11.6893","article-title":"Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4","volume":"166","author":"Im","year":"2001","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib89","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/72162","article-title":"Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand","volume":"6","author":"Kawai","year":"2000","journal-title":"Nat Med"},{"key":"10.1007\/s13311-015-0398-y_bib90","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/imt.15.1","article-title":"Novel insights into anti-CD40\/CD154 immunotherapy in transplant tolerance","volume":"7","author":"Pinelli","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1007\/s13311-015-0398-y_bib91","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-8722-7-44","article-title":"A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors","volume":"7","author":"de Vos","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1007\/s13311-015-0398-y_bib92","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/ajt.12678","article-title":"Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects","volume":"14","author":"Okimura","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1007\/s13311-015-0398-y_bib93","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/eji.200424973","article-title":"Antagonist anti-human CD40 antibody inhibits germinal center formation in cynomolgus monkeys","volume":"34","author":"de Vos","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib94","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1007\/s13311-015-0398-y_bib95","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/eji.201445101","article-title":"With a little help from my old T cell: memory follicular T helper cells driving autoimmunity?","volume":"44","author":"Winkler","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jneuroim.2012.12.001","article-title":"Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis","volume":"256","author":"Luo","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0398-y_bib97","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-015-0398-y_bib98","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0398-y_bib99","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mus.23412","article-title":"Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study","volume":"46","author":"Collongues","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0398-y_bib100","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/mus.24063","article-title":"Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment","volume":"48","author":"Yi","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0398-y_bib101","first-page":"1243","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"22","author":"Mysler","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1007\/s13311-015-0398-y_bib102","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib103","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4049\/jimmunol.1401329","article-title":"B10 cells: a functionally defined regulatory B cell subset","volume":"194","author":"Tedder","year":"2015","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib104","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.23951","article-title":"Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis","volume":"49","author":"Sun","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0398-y_bib105","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-015-0398-y_bib106","first-page":"939520","article-title":"B-cell-activating factor and autoimmune myasthenia gravis","volume":"2011","author":"Ragheb","year":"2011","journal-title":"Autoimmune Dis"},{"key":"10.1007\/s13311-015-0398-y_bib107","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","article-title":"A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis","volume":"65","author":"Ragheb","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib108","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1056\/NEJMct1207259","article-title":"Belimumab for systemic lupus erythematosus","volume":"368","author":"Hahn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0398-y_bib109","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00281-014-0427-7","article-title":"Targeting B cells and autoantibodies in the therapy of autoimmune diseases","volume":"36","author":"Kao","year":"2014","journal-title":"Semin Immunopathol"},{"key":"10.1007\/s13311-015-0398-y_bib110","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"10.1007\/s13311-015-0398-y_bib111","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"10.1007\/s13311-015-0398-y_bib112","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2217\/fon.14.30","article-title":"Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials","volume":"10","author":"Huang","year":"2014","journal-title":"Future Oncol"},{"key":"10.1007\/s13311-015-0398-y_bib113","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-015-0529-1","article-title":"Proteasome inhibitors as experimental therapeutics of autoimmune diseases","volume":"17","author":"Verbrugge","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1007\/s13311-015-0398-y_bib114","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib115","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.4049\/jimmunol.1301555","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients","volume":"193","author":"Gomez","year":"2014","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib116","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1007\/s13311-015-0398-y_bib117","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1007\/s13311-015-0398-y_bib118","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/ni.2939","article-title":"Type I and type II Fc receptors regulate innate and adaptive immunity","volume":"15","author":"Pincetic","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib119","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"10.1007\/s13311-015-0398-y_bib120","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3389\/fimmu.2014.00674","article-title":"Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all?","volume":"5","author":"Nagelkerke","year":"2015","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib121","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaut.2013.12.014","article-title":"Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis","volume":"52","author":"Thiruppathi","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1007\/s13311-015-0398-y_bib122","first-page":"249","article-title":"FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions","volume":"382","author":"Challa","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib123","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib124","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.4049\/jimmunol.1003412","article-title":"Antibody-mediated coengagement of Fc\u03b3RIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus","volume":"186","author":"Horton","year":"2011","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib125","unstructured":"Alexion. Pharmaceuticals Inc. Soliris. Eculizumab prescribing information. 2014."},{"key":"10.1007\/s13311-015-0398-y_bib126","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005072-197803000-00008","article-title":"Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis","volume":"37","author":"Sahashi","year":"1978","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-015-0398-y_bib127","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1084\/jem.147.4.973","article-title":"Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis","volume":"147","author":"Lennon","year":"1978","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-015-0398-y_bib128","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0398-y_bib129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0022-1759(85)90247-9","article-title":"A triple antibody assay for the quantitation of plasma IgG subclass antibodies to acetylcholine receptors in patients with myasthenia gravis","volume":"83","author":"Nielsen","year":"1985","journal-title":"J Immunol Methods"},{"key":"10.1007\/s13311-015-0398-y_bib130","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"Rodgaard","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib131","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"MG Study Group. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0398-y_bib132","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1517\/14712598.2015.1045410","article-title":"Brodalumab\u2014an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis","volume":"15","author":"Bauer","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1007\/s13311-015-0398-y_bib133","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1586\/1744666X.2015.1023295","article-title":"Ixekizumab for treatment of psoriasis","volume":"11","author":"Dyring-Andersen","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib134","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2014.04.001","article-title":"The immune potential and immunopathology of cytokine-producing B cell subsets: a comprehensive review","volume":"55","author":"Bao","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1007\/s13311-015-0398-y_bib135","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4049\/jimmunol.169.2.1077","article-title":"Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production","volume":"169","author":"Deng","year":"2002","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib136","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"key":"10.1007\/s13311-015-0398-y_bib137","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3899\/jrheum.140665","article-title":"MUSASHI Study Investigators. Longterm safety and efficacy of subcutaneous tocilizumab monotherapy: results from the 2-year open-label extension of the MUSASHI study","volume":"42","author":"Ogata","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-015-0398-y_bib138","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/07853890.2013.771986","article-title":"Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases","volume":"45","author":"Alten","year":"2013","journal-title":"Ann Med"},{"key":"10.1007\/s13311-015-0398-y_bib139","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0398-y_bib140","doi-asserted-by":"crossref","unstructured":"Bhattacharya P, Thiruppathi M, Elshabrawy HA, Alharshawi K, Kumar P, Prabhakar BS. GM-CSF: an immune modulatory cytokine that can suppress autoimmunity. Cytokine 2015.","DOI":"10.1016\/j.cyto.2015.05.030"},{"key":"10.1007\/s13311-015-0398-y_bib141","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.4049\/jimmunol.177.8.5296","article-title":"Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells","volume":"177","author":"Sheng","year":"2006","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib142","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clim.2008.03.509","article-title":"Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis","volume":"128","author":"Sheng","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib143","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneuroim.2011.10.010","article-title":"GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis","volume":"240-241","author":"Sheng","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0398-y_bib144","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1749-6632.2012.06840.x","article-title":"Functional defect in regulatory T cells in myasthenia gravis","volume":"1274","author":"Thiruppathi","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-015-0398-y_bib145","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/mus.23488","article-title":"Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells","volume":"46","author":"Rowin","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0398-y_bib146","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1073\/pnas.040554597","article-title":"Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice","volume":"97","author":"Paas-Rozner","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0398-y_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(97)00232-3","article-title":"Nasal administration of multiple antigens suppresses experimental autoimmune myasthenia gravis, encephalomyelitis and neuritis","volume":"155","author":"Shi","year":"1998","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-015-0398-y_bib148","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.4049\/jimmunol.1401392","article-title":"Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis","volume":"193","author":"Luo","year":"2014","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0398-y_bib149","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/j.seminhematol.2007.08.001","article-title":"Autologous stem cell transplantation in autoimmune diseases","volume":"44","author":"Passweg","year":"2007","journal-title":"Semin Hematol"},{"key":"10.1007\/s13311-015-0398-y_bib150","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/mus.22176","article-title":"Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia","volume":"44","author":"Liewluck","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0398-y_bib151","doi-asserted-by":"crossref","first-page":"e87840","DOI":"10.1371\/journal.pone.0087840","article-title":"Effects of the \u03b22-adrenoceptor agonist albuterol in a mouse model of anti-MuSK myasthenia gravis","volume":"9","author":"Ghazanfari","year":"2014","journal-title":"PLoS One"},{"key":"10.1007\/s13311-015-0398-y_bib152","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1113\/jphysiol.2013.251827","article-title":"Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody","volume":"591","author":"Morsch","year":"2013","journal-title":"J Physiol"},{"key":"10.1007\/s13311-015-0398-y_bib153","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.nmd.2013.07.010","article-title":"Muscle specific kinase autoimmune myasthenia gravis in children: a case series","volume":"23","author":"Skjei","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-015-0398-y_bib154","first-page":"1531","article-title":"Neuregulin-1 potentiates agrin-induced acetylcholine receptor clustering through muscle-specific kinase phosphorylation","volume":"125","author":"Ngo","year":"2012","journal-title":"J Cell Sci"},{"key":"10.1007\/s13311-015-0398-y_bib155","doi-asserted-by":"crossref","first-page":"E2543","DOI":"10.1073\/pnas.1418289112","article-title":"Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the \u03b17 nicotinic acetylcholine receptor","volume":"112","author":"Spurny","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0398-y_bib156","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.2618","article-title":"Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases","volume":"18","author":"Russell","year":"2012","journal-title":"Nat Med"},{"key":"10.1007\/s13311-015-0398-y_bib157","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s13311-015-0345-y","article-title":"A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis","volume":"12","author":"Sanders","year":"2015","journal-title":"Neurotherapeutics"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0398-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0398-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0398-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:48:10Z","timestamp":1761806890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923009443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":157,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1878747923009443"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0398-y","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0398-y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}